Are sodium-glucose cotransporter-2 inhibitors safe adjunctive drugs during insulin therapy in young children with type 1 diabetes? The first case of type 1 diabetes with SLC5A2 mutation.

1 型糖尿病患儿胰岛素治疗期间钠 - 葡萄糖协同转运蛋白 - 2 抑制剂是否安全辅助药物 ？ 首例 SLC5A2 突变的 1 型糖尿病.

• 影响指数: 4.53
• 发表时间: 2024 Jul
• 来源期刊: J Diabetes
• DOI: 10.1111/1753-0407.13570
• PMID: 38923174
• 文章类型: Case Reports
• 中科院分区: Q3
• 方向: 医学
• 作者列表: Ahangar Davoodi M,Daneshmand MA,Rezaei T

Mesh: Humans; Sodium-Glucose Transporter 2 Inhibitors / therapeutic use adverse effects; Diabetes Mellitus, Type 1 / drug therapy genetics; Sodium-Glucose Transporter 2 / genetics; Insulin / therapeutic use; Mutation; Child, Preschool; Hypoglycemic Agents / therapeutic use; Male; Blood Glucose / metabolism analysis drug effects; Female; Hypoglycemia / chemically induced genetics; Glycated Hemoglobin / analysis metabolism; Drug Therapy, Combination

Abstract

Highlights A persistent glycosuria alongside hypoglycemia in pediatric type 1 diabetes mellitus needs further evaluation. Morning hypoglycemia is a limiting side effect of sodium glucose transporter 2 (SGLT2) inhibitors in children younger than 5 years old. SLC5A2 mutation functioning as a SGLT2 inhibitor can result in acceptable range of glycated hemoglobin in younger children and lower required doses of insulin.

摘要

强调小儿1型糖尿病的持续性糖尿和低血糖需要进一步评估。早晨低血糖是钠葡萄糖转运蛋白2（SGLT2）抑制剂在5岁以下儿童中的限制性副作用。充当SGLT2抑制剂的SLC5A2突变可导致年幼儿童中糖化血红蛋白的可接受范围和较低的所需胰岛素剂量。